Azome Therapeutics:
Advancing treatment of severe inflammatory disease
Background
Azome Therapeutics is an early-stage drug discovery company focused on advancing treatment of severe inflammatory diseases. The company’s RHAMM-antagonist platform blocks NLRP3 inflammasome activation, and its lead drug candidate, AZM-152, has demonstrated significant preclinical potential in a number of severe inflammatory diseases, including several that have significant unmet needs.
Approach
Since mid 2023, NVision has been working closely with Azome leadership to develop a compelling narrative for potential investors. This has included new branding, a new website, and presentation materials as well as the development and management of an ongoing and consistent newsflow of information, designed to differentiate the company and its core platform technology. In fall 2024, the company announced that it has entered a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS) to investigate AZM-152 to prevent BPD.
